Du Lina, Zhang Xiaopeng, Han Yong Y, Burke Nancy A, Kochanek Patrick M, Watkins Simon C, Graham Steven H, Carcillo Joseph A, Szabó Csaba, Clark Robert S B
Department of Critical Care Medicine, University of Pittsburgh, Safar Center for Resuscitation Research, Pittsburgh, Pennsylvania 15260, USA.
J Biol Chem. 2003 May 16;278(20):18426-33. doi: 10.1074/jbc.M301295200. Epub 2003 Mar 7.
Poly(ADP-ribosylation), primarily via poly(ADP-ribose) polymerase-1 (PARP-1), is a pluripotent cellular process important for maintenance of genomic integrity and RNA transcription in cells. However, during conditions of oxidative stress and energy depletion, poly(ADP-ribosylation) paradoxically contributes to mitochondrial failure and cell death. Although it has been presumed that poly(ADP-ribosylation) within the nucleus mediates this pathologic process, PARP-1 and other poly(ADP-ribosyltransferases) are also localized within mitochondria. To this end, the presence of PARP-1 and poly(ADP-ribosylation) were verified within mitochondrial fractions from primary cortical neurons and fibroblasts. Inhibition of poly(ADP-ribosylation) within the mitochondrial compartment preserved transmembrane potential (DeltaPsi(m)), NAD(+) content, and cellular respiration, prevented release of apoptosis-inducing factor, and reduced neuronal cell death triggered by oxidative stress. Treatment with liposomal NAD(+) also preserved DeltaPsi(m) and cellular respiration during oxidative stress. Furthermore, inhibition of poly(ADP-ribosylation) prevented intranuclear localization of apoptosis-inducing factor and protected neurons from excitotoxic injury; and PARP-1 null fibroblasts were protected from oxidative stress-induced cell death. Collectively these data suggest that poly(ADP-ribosylation) compartmentalized to the mitochondria can be converted from a homeostatic process to a mechanism of cell death when oxidative stress is accompanied by energy depletion. These data implicate intra-mitochondrial poly(ADP-ribosylation) as an important therapeutic target for central nervous system and other diseases associated with oxidative stress and energy failure.
聚(ADP-核糖基化)主要通过聚(ADP-核糖)聚合酶-1(PARP-1)进行,是一种多能细胞过程,对维持细胞基因组完整性和RNA转录非常重要。然而,在氧化应激和能量耗竭的情况下,聚(ADP-核糖基化)却反常地导致线粒体功能衰竭和细胞死亡。尽管人们推测细胞核内的聚(ADP-核糖基化)介导了这一病理过程,但PARP-1和其他聚(ADP-核糖基转移酶)也定位于线粒体中。为此,在原代皮质神经元和成纤维细胞的线粒体组分中验证了PARP-1和聚(ADP-核糖基化)的存在。抑制线粒体区室中的聚(ADP-核糖基化)可维持跨膜电位(ΔΨm)、NAD⁺含量和细胞呼吸,防止凋亡诱导因子的释放,并减少氧化应激引发的神经元细胞死亡。用脂质体NAD⁺处理也能在氧化应激期间维持ΔΨm和细胞呼吸。此外,抑制聚(ADP-核糖基化)可防止凋亡诱导因子的核内定位,并保护神经元免受兴奋性毒性损伤;PARP-1基因敲除的成纤维细胞可免受氧化应激诱导的细胞死亡。这些数据共同表明,当氧化应激伴有能量耗竭时,定位于线粒体的聚(ADP-核糖基化)可从一种稳态过程转变为细胞死亡机制。这些数据表明线粒体内的聚(ADP-核糖基化)是中枢神经系统和其他与氧化应激及能量衰竭相关疾病的重要治疗靶点。